Clinical Trial Update: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

View source ↗

Summary

This ClinicalTrials.gov entry describes a prospective registry evaluating an antibody-drug conjugate as first- and second-line therapy for breast cancer, sponso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: University of California, San Francisco | Conditions: HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma | Status: RECRUITING